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AbstrAct
Background Steroids are frequently used in patients 
with metastatic non-small cell lung cancer (mNSCLC), 
but they could be detrimental for patients treated with 
immune checkpoint inhibitors (ICIs). Here, we assessed 
the association between early use of steroids, clinical 
outcomes and peripheral immune blood cells modulation 
in patients with mNSCLC treated with ICIs.
Methods We reviewed patients with mNSCLC treated at 
our institution between April 2013 and December 2017. 
Early use of steroids was defined as the use of a daily 
prednisone-equivalent dose ≥10 mg for at least 1 day 
within 28 days after ICI initiation. Peripheral immune blood 
cell counts were retrieved at baseline and at 4 and 6 
weeks after ICI initiation.
Results Out of 151 patients included, 35 (23%) made 
early use of steroids that was associated with poor 
disease control (OR 0.32, p=0.006), progression-free 
survival (HR 1.80, p=0.003) and overall survival (HR 2.60, 
p<0.001). Early use of steroids significantly correlated with 
higher median absolute neutrophil count, neutrophil to 
lymphocyte ratio (NLR) and derived NLR, and lower median 
absolute and relative eosinophil count, both at 4 and 6 
weeks after ICI initiation.
Conclusions In patients with mNSCLC treated with ICIs, 
early use of steroids was associated with worse clinical 
outcomes and remarkable modulation of peripheral 
blood immune cells, which could contribute to restraining 
the activation of antitumour immunity. If confirmed in 
prospective studies, these findings would highlight the 
importance of carefully evaluating and, whenever possible, 
avoiding steroids during early phases of ICI treatment.
BaCkgRound
Metastatic non-small cell lung cancer 
(NSCLC) is the leading cause of cancer-re-
lated death worldwide.1 In recent years, the 
advent of immunotherapy has deeply modi-
fied the treatment paradigm of metastatic 
Key questions
What is already known about this subject?
 ► Earlier this year, the deleterious impact of baseline 
early steroids on the efficacy of PD-1 (Programmed 
cell Death protein-1)/PD-L1 (Programmed cell 
Death-Ligand 1) blockade in patients with non-
small-cell lung cancer (NSCLC) was reported.
 ► Similarly, a brief report showed the scant overall 
survival associated with the early use of systemic 
corticosteroids in patients with advanced NSCLC 
treated with nivolumab.
 ► However, the major critic to the postulation that the 
baseline/early use of steroids can directly impair 
immune checkpoint inhibitor (ICI) efficacy is that a 
precocious requirement of steroidal therapy in pa-
tients with advanced NSCLC could be due to a rapid 
clinical worsening/progression, being the early use 
of steroids the consequence, instead of the cause, of 
worse clinical outcomes.
What does this study add?
 ► Our data indicate that an early use of steroids can 
directly impact on ICI efficacy by modulating periph-
eral blood immune cells profile, and even if further 
studies are required to validate the role of neutro-
phils, lymphocytes and eosinophils modulation, our 
study suggests the biological basis behind the inter-
action between early use of steroids and ICI efficacy.
How might this impact on clinical practice?
 ► Our findings discourage the use of steroids during 
the first 4 weeks of ICI treatment in patients with 
advanced NSCLC.
 ► Since early initiation of steroids, or its chronic use, 
cannot be avoided in some patients, chemotherapy 
could be a preferred treatment option in these cases.
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NSCLC without a genetic driver.2 Indeed, several clinical 
trials have shown superior efficacy of immune checkpoint 
inhibitors (ICIs) over chemotherapy, with the result of 
improving disease control, progression-free survival (PFS) 
and overall survival (OS). Consequently, anti-PD-1/PD-L1 
agents have entered clinical practice in first and more 
advanced lines of therapy.3–6
Despite the efficacy of ICIs, only a limited number of 
patients actually benefit from these agents. Different predic-
tive factors have been investigated in an effort to explain 
the heterogeneous response to ICIs, with high PD-L1 
expression and high tumour mutational burden having 
emerged as predictive of clinical benefit and improved 
patient survival.7 8 More recently, the neutrophil to lympho-
cyte ratio (NLR), which reflects systemic inflammation and 
immune system activation, demonstrated a prognostic and 
predictive role in patients with advanced NSCLC treated 
with ICIs.9–14 Therefore, it is highly likely that a complex 
interaction between tumour genetic/epigenetic and host 
factors crucially contributes to determine the efficacy of 
immunotherapy in individual patients.15 16 In this view, a 
critical role could be played by concomitant therapies, espe-
cially those that affect the immune cell populations (eg, 
immune-suppressive agents), which could prevent ICI-in-
duced enhancement of antitumour immune response.17 In 
particular, the use of steroids, prescribed to patients with 
cancer for several medical conditions (eg, dyspnoea, pain, 
brain metastases, spinal cord compression, treatment-re-
lated adverse events),18 is controversial. Recent reports 
from ‘real-world’ practice have shown that use of steroids at 
the initiation of treatment with ICIs is associated with lower 
response rate and shorter survival in patients with advanced 
NSCLC.19 20 Conversely, retrospective data showed that the 
use of steroids for immune-related adverse events (irAEs) 
during anti PD-1 treatment did not significantly affect 
patients’ survival.21 Therefore, the impact of steroids use 
on ICI efficacy in patients with metastatic NSCLC remains 
controversial.
In this study, we performed a retrospective cohort study 
to investigate the impact of early steroid use on the prog-
nosis of patients with metastatic NSCLC treated with ICIs at 
our institution. Since corticosteroids can modulate periph-
eral immune blood cells,22 we explored the association 
between early use of steroids and modification in periph-
eral immune blood cells profile.
MetHods
Patients’ population
We reviewed all patients with metastatic NSCLC treated 
with ICIs at the Fondazione IRCCS Istituto Nazionale dei Tumori 
di Milano between April 2013 and December 2017 and 
included in the APOLLO prospective observational registry. 
Patients evaluable for tumour response according to the 
RECIST (Response Evaluation Criteria In Solid Tumours) 
V.1.1 criteria23 were evaluated, and data on demographics, 
clinical and pathological characteristics, as well as data 
on ICI treatment, clinical outcomes, use of steroids, and 
absolute and differential peripheral white blood cell counts, 
at baseline and at 4 weeks and 6 weeks after ICI initiations 
were retrieved. We also calculated the NLR by dividing the 
absolute neutrophil count (ANC) by the absolute lympho-
cyte count (ALC), and the derived NLR (dNLR) by dividing 
the ANC by the difference of white blood count (WBC) 
minus the ANC. Based on available literature reporting on 
the association between peripheral blood immune cells-
based indexes and clinical outcomes of patients with cancer 
treated with immunotherapy,13 24–27 we used a cut-off value 
of 5 for NLR, 3 for dNLR and 1.5 for the relative eosinophil 
count (REC).
Early use of steroids was defined as the use of a daily 
prednisone-equivalent dose ≥10 mg for at least 1 day within 
28 days after ICI initiation. Patients who made early use of 
steroids were included in the exposed cohort, while the 
remaining patients were included in the control cohort.
statistical analyses
Descriptive statistics were used to summarise patients’ char-
acteristics. χ2 test or Fisher’s exact test, as appropriate, was 
used to analyse the association between early use of steroids 
and relevant clinical, pathological and laboratory features. 
PFS was defined as the time between ICI treatment initi-
ation and radiological documentation of disease progres-
sion or patient death from any cause, whichever came first. 
OS was defined as the time between ICI treatment initia-
tion and patient death from any cause. PFS and OS prob-
abilities were calculated with the Kaplan-Meier method, 
and survival curves were compared with the log-rank test. 
The reverse Kaplan-Meier method was used for follow-up 
quantification.28 We used Cox proportional hazard model 
to assess the impact of individual variables on PFS and OS 
(univariable analysis); variables significantly associated 
with clinical outcomes were then included in a multivari-
able model. Results of Cox proportional hazard model 
analyses were reported as HR and 95% CIs. Peripheral 
blood immune cell counts and indexes in the control and 
exposed cohorts were visually described by means of water-
fall plots and box plots. Two-sample Wilcoxon test was used 
to compare the median values of peripheral white blood 
cells counts and indexes between the control and exposed 
cohorts at different time points. Statistical analyses were 
performed using R (V.3.5.0) and RStudio (V.1.1.456) soft-
ware. Statistical significance threshold for all statistical tests 
and survival analyses was set at p<0.05.
Results
Patients’ characteristics
Out of 151 patients included, 83 (55%) received ster-
oids at any time during ICI treatment, while 35 (23%) 
made early use of steroids. Patients’ characteristics in 
the entire population or according to the early use of 
steroids are summarised in table 1. Six patients (4%) 
received combinatorial PD-L1 and CTLA-4 blockade, 
while 145 (96%) received single-agent anti PD-1/PD-L1 
treatment. Early use of steroids was associated with an 
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Table 1 Characteristics of the patients of the entire study population and according to the early use of steroids
Characteristics
Total
(N=151)
n (%)
Control cohort
(n=116)
n (%)
Exposed cohort
(n=35)
n (%) OR (95% CI) P value
Age (years) <65 64 (42) 45 (39) 19 (54) – 0.12
≥65 87 (58) 71 (61) 16 (46)
Gender Male 89 (59) 73 (63) 16 (46) – 0.08
Female 62 (41) 43 (37) 19 (54)
Smoking Never or former 103 (71) 83 (75) 20 (57) – 0.06
Current 43 (29) 28 (25) 15 (43)
NA 5 5 0
ECOG PS 0–1 142 (94) 112 (97) 30 (86) 4.57 (1.10 to 20.37) 0.03
≥2 9 (6) 4 (3) 5 (14)
Histology Squamous 33 (22) 29 (25) 4 (11) – 0.11
Non-squamous 118 (78) 87 (75) 31 (89)
PD-L1 status Negative 46 (51) 37 (51) 9 (47) – 0.80
Positive 45 (49) 35 (49) 10 (53)
NA 60 44 16
Metastatic sites (N) 1–2 65 (43) 57 (49) 8 (23) 3.20 (1.38 to 8.16) 0.006
>2 86 (57) 59 (51) 27 (77)
Brain mets No 118 (78) 99 (85) 19 (54) 4.83 (2.07 to 11.41) <0.001
Yes 33 (22) 17 (15) 16 (46)
Liver mets No 117 (77) 89 (77) 28 (80) – 0.68
Yes 34 (23) 27 (23) 7 (20)
Bone mets No 87 (58) 72 (62) 15 (43) – 0.05
Yes 64 (42) 44 (38) 20 (57)
Line of treatment 1–2 85 (56) 65 (56) 20 (57) – 1
>2 66 (44) 51 (44) 15 (43)
ICI regimen Mono 145 (96) 110 (95) 35 (100) – 0.34
Dual 6 (4) 6 (5) 0 (0)
P values below the significance threshold are reported in bold.
ECOG PS, Eastern Cooperative Oncology Group Performance Status; ICI, immune checkpoint inhibitor; NA, not available.
Eastern Cooperative Oncology Group Performance 
Status (ECOG PS) ≥2 (OR 4.57, 95% CI 1.10 to 20.37, 
p=0.03), the presence of brain metastases (OR 4.83, 
95% CI 2.07 to 11.41, p<0.001) and number of meta-
static sites >2 (OR 3.08, 95% CI 1.33 to 7.89, p=0.01), 
while no association was observed with patients’ age, 
gender, smoking status, tumour histology, PD-L1 status, 
liver or bone metastases, line of ICI treatment, or ICI 
regimen. In 19 out of 35 patients in the exposed cohort 
(54%), treatment with steroids was already ongoing at 
the time of ICI initiation with the purpose of supportive 
care medication (baseline use of steroids), while the 
remaining 16 patients (46%) started steroids during the 
first 28 days after ICI initiation (baseline steroids-naive 
patients). In the latter case, only four patients received 
steroids because of irAEs. The median number of days 
on steroids within the first 4 weeks of ICI treatment was 
28 (range, 1–28). The median total prednisone-equiva-
lent dose of steroids within the first 4 weeks of ICI treat-
ment was 280 mg (range, 20–875 mg).
Impact of early steroids use on clinical outcomes
In the exposed cohort, we observed one complete 
response (CR), 5 partial responses (PR), 6 disease 
stabilisations (SD) and 23 disease progressions as best 
response, while 28 PR, 44 stabilisations and 44 progres-
sions occurred in the control group. Overall, patients 
in the exposed cohort had a 68% lower probability to 
achieve disease control (CR+PR+SD) than patients in the 
control cohort, with a disease control rate of 34% vs 62%, 
respectively (OR 0.32, 95% CI 0.14 to 0.71, p=0.006). No 
significant differences in the objective response rate were 
observed (p=0.39).
With a median follow-up time of 28.6 months, the median 
PFS for patients in the exposed and control cohorts was 
1.98 months and 3.94 months, respectively (HR 1.80, 95% 
CI 1.20 to 2.80, p=0.003) (figure 1A). In the multivariable 
model including other covariates significantly associated 
with PFS (ie, ECOG PS and tumour PD-L1 expression), 
early use of steroids was independently associated with 
poorer PFS (HR 1.88, 95% CI 1.08 to 3.28, p=0.03) 
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Figure 1 Kaplan-Meier curves for (A) progression-free survival (PFS) and (B) overall survival (OS) according to the early use of 
steroids. Blue line indicates patients in the control cohort, while red line indicates patients in the exposed cohort.
Table 2 Cox proportional hazards models for progression-free survival
Characteristics
Univariate analyses Multivariable model
HR (95% CI) P value HR (95% CI) P value
Age ≥65 vs <65 – 0.74 – –
Gender Female vs male – 0.80 – –
Smoking Current vs never/former – 0.62 – –
ECOG PS 2 vs 0–1 2.10 (1.00 to 4.10) 0.04 4.83 (1.42 to 16.40) 0.01
Histology Squamous vs non-squamous – 0.51 – –
PD-L1 status Positive vs negative 0.56 (0.36 to 0.88) 0.01 0.48 (0.30 to 0.77) 0.002
Metastatic sites (N) >2 vs 1–2 – 0.13 – –
Brain mets Yes vs no – 0.22 – –
Liver mets Yes vs no – 0.09 – –
Bone mets Yes vs no – 0.05 – –
Line of treatment >2 vs 1–2 – 0.84 – –
ICI regimen Mono vs dual – 0.08 – –
Early use of steroids Yes vs no 1.80 (1.20 to 2.80) 0.003 1.88 (1.08 to 3.28) 0.03
P values below the significance threshold are reported in bold.
ECOG PS, Eastern Cooperative Oncology Group Performance Status; ICI, immune checkpoint inhibitor.
(table 2). Patients in the exposed cohort also had a lower 
median OS when compared with patients in the control 
cohort (4.86 vs 15.14 months, respectively; HR 2.60, 95% 
CI 1.70 to 4.10, p<0.001) (figure 1B). The impact of early 
use of steroids on OS remained significant after adjusting 
for other covariates associated with OS (HR 2.38, 95% CI 
1.49 to 3.81, p<0.001) (table 3). No differences in PFS or 
OS were observed in the entire study population, between 
patients who received steroids at any time during ICI treat-
ment and patients who did not (median OS 5.4 months vs 
4.7 months, respectively; p=0.65) (online supplementary 
figure 1). Notably, among patients in the control cohort, 
a better PFS (HR 0.62, 95% CI 0.42 to 0.93, p=0.02) and a 
trend towards a better OS (HR 0.80, 95% CI 0.50 to 1.28, 
p=0.35) were observed in patients who received steroids 
after 28 days from ICI initiation with respect to patients 
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Table 3 Cox proportional hazards models for overall survival
Characteristics
Univariate analyses Multivariable model
HR (95% CI) P value HR (95% CI) P value
Age ≥65 vs <65 – 0.97 – –
Gender Female vs male – 0.81 – –
Smoking Current vs never/former – 0.93 – –
ECOG PS 2 vs 0–1 3.60 (1.70 to 7.60) <0.001 2.24 (1.01 to 4.95) 0.04
Histology Non-squamous vs squamous – 0.13 – –
PD-L1 status Positive vs negative – 0.20 – –
Metastatic sites (N) >2 vs 1–2 – 0.22 – –
Brain mets Yes vs no – 0.37
Liver mets Yes vs no – 0.05
Bone mets Yes vs no – 0.03 – 0.09
Line of treatment >2 vs 1–2 – 0.85 – –
ICI regimen Dual vs mono – 0.93 – –
Early use of steroids Yes vs no 2.60 (1.70 to 4.10) <0.001 2.38 (1.48 to 3.83) <0.001
P values below the significance threshold are reported in bold.
ECOG PS, Eastern Cooperative Oncology Group Performance Status; ICI, immune checkpoint inhibitor.
Table 4 Median peripheral blood immune cell counts and 
indexes at baseline according to the baseline use of steroids
No baseline steroids Baseline steroids P 
value*Median IQR Median IQR
WBC† 7.20 6.05–9.09 11.28 9.40–13.24 <0.001
ANC† 5.00 3.95–6.45 8.80 7.13–10.53 <0.001
ALC† 1.40 1.00–1.90 1.30 0.95–1.65 0.48
AMC† 0.50 0.40–0.60 0.60 0.43–080 0.01
AEC† 0.20 0.10–0.30 0.10 0.00–0.18 0.01
REC‡ 2.30 1.40–3.82 1.00 0.00–1.45 <0.001
ABC† 0.00 0.00–0.00 0.00 0.00–0.00 0.84
NLR 3.40 2.50–5.40 6.90 4.20–9.20 <0.001
dNLR 2.10 1.70–3.00 3.40 3.00–4.70 <0.001
P values below the significance threshold are reported in bold.
*Wilcoxon test
†×103.
‡%.
ABC, absolute basophil count; AEC, absolute eosinophil count; 
ALC, absolute lymphocyte count; AMC, absolute monocyte 
count; ANC, absolute neutrophil count; dNLR, derived neutrophil 
to lymphocyte ratio.NLR, neutrophil to lymphocyte ratio; REC, 
relative eosinophil count; WBC, white blood count;
who did not receive steroids at any time during the ICI 
treatment (online supplementary figure 2). Furthermore, 
when we restricted the analysis to the exposed cohort, we 
found no differences between patients with baseline use 
of steroids and patients who were steroids-naive at base-
line (median PFS 1.9 months vs 2.1 months, respectively, 
log-rank p=0.22; median OS 4.7 months vs 5.4 months, 
respectively, log-rank p=0.70).
association between early use of steroids and modulation of 
peripheral blood immune cells
Peripheral blood immune cell counts were available at 
baseline for 147 patients, at 4 weeks after ICI initiations 
for 146 patients and at 6 weeks after ICI initiation for 142 
patients.
Patients taking steroids at the time of ICI initiation had 
higher baseline median WBC (11 280 vs 7200; p<0.001), 
ANC (8800 vs 5000; p<0.001), absolute monocyte count 
(AMC) (600 vs 500; p=0.01), NLR (6.9 vs 3.4; p<0.001) 
and dNLR (3.4 vs 2.1), and lower median absolute eosin-
ophil count (AEC) (100 vs 200; p=0.01) and REC (1.0 vs 
2.3; p<0.001), with respect to all other patients (table 4). 
Furthermore, patients with baseline use of steroids had 
a higher chance of having an NLR ≥5 (OR 5.40, 95% CI 
1.95 to 16.70, p<0.001) and a dNLR ≥3 (OR 10.32, 95% 
CI 3.43 to 39.43, p<0.001), and a lower chance of having 
an REC ≥1.5 (OR 0.14, 95% CI 0.04 to 0.41, p<0.001), 
with respect to all other patients (online supplementary 
table 1). No differences in baseline peripheral blood cells 
were observed between baseline steroids-naive patients 
in the exposed cohort and patients in the control cohort 
(online supplementary table 2 and online supplementary 
table 3).
At 4 weeks after ICI initiation, patients in the exposed 
cohort had a higher median WBC (8760 vs 7520; p<0.001), 
ANC (7000 vs 5000; p<0.001), NLR (6.9 vs 3.4; p<0.001) 
and dNLR (3.6 vs 2.0; p<0.001), and a lower median AEC 
(100 vs 200; p=0.009) and REC (1.2 vs 2.6; p<0.001), when 
compared with patients in the control cohort (table 5). 
Conversely, no differences were observed in median ALC, 
AMC and absolute basophil count. Similar findings were 
observed at 6 weeks after ICI initiation, with the excep-
tion of median ALC which was lower for patients in the 
exposed cohort (1000 vs 1500; p=0.004). We confirmed 
these data when peripheral blood immune cell counts/
indexes were treated as dichotomous variables by using 
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Table 5 Median peripheral blood immune cell counts and indexes at 4 and 6 weeks after ICI initiation according to the early 
use of steroids
4 weeks 6 weeks
Control cohort Exposed cohort
P value*
Control cohort Exposed cohort
P value*Median IQR Median IQR Median IQR Median IQR
WBC† 7.52 6.22–8.94 8.76 8.08–12.20 <0.001 7.75 6.19–9.73 8.67 7.35–11.22 0.01
ANC† 5.00 3.80–6.20 7.00 5.60–9.70 <0.001 5.15 3.70–6.90 7.45 5.78–8.73 <0.001
ALC† 1.50 1.00–1.90 1.10 0.80–1.70 0.07 1.50 1.10–1.90 1.0 0.70–1.70 0.004
AMC† 0.50 0.40–0.60 0.60 0.50–0.60 0.08 0.50 0.40–0.60 0.50 0.40–0.70 0.82
AEC† 0.20 0.10–0.30 0.10 0.10–0.20 0.009 0.20 0.10–0.30 0.10 0.00–0.20 <0.001
REC‡ 2.60 1.50–3.80 1.20 0.70–3.30 <0.001 2.35 1.30–3.90 1.20 0.00–2.40 <0.001
ABC† 0.00 0.00–0.10 0.00 0.00–0.00 0.46 0.00 0.00–0.10 0.00 0.00–0.10 0.61
NLR 3.4 2.4–5.2 6.9 3.5–10.6 <0.001 3.6 2.4–5.4 8.1 3.2–14.6 <0.001
dNLR 2.0 1.6–2.8 3.6 2.6–4.9 <0.001 2.2 1.6–3.0 4.0 2.3–5.8 <0.001
P values below the significance threshold are reported in bold.
*Wilcoxon test.
†×103.
‡%.
ABC, absolute basophil count; AEC, absolute eosinophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, 
absolute neutrophil count; dNLR, derived neutrophil to lymphocyte ratio.ICI, immune checkpoint inhibitor; NLR, neutrophil to lymphocyte 
ratio; REC, relative eosinophil count; WBC, white blood count;
established thresholds. In particular, at 4 weeks after ICI 
initiation, early use of steroids was positively associated 
with an NLR ≥5 (OR 4.01, 95% CI 1.79 to 9.28, p<0.001) 
and a dNLR ≥3 (OR 5.60, 95% CI 2.46 to 13.24, p<0.001), 
and negatively associated with an REC ≥1.5 (OR 0.15, 
95% CI 0.06 to 0.33, p<0.001) (online supplementary 
table 4). Of note, at 4 and 6 weeks NLR ≥5, dNLR ≥3 and 
REC <1.5 were associated with worse clinical outcomes in 
our study population (online supplementary figure 3 and 
online supplementary figure 4) .
dIsCussIon
Steroids are frequently used in patients with advanced 
NSCLC, especially with the aim of palliating symptoms, or 
for the management of adverse events related to different 
treatments (eg, radiotherapy, chemotherapy or immuno-
therapy). However, patients receiving steroids have typi-
cally been excluded from clinical trials investigating ICIs.
In the present study, we showed that, in patients with 
metastatic NSCLC treated with ICIs, the early use of 
steroids was associated with poor disease control (OR 0.32, 
95% CI 0.14 to 0.71, p=0.006), low PFS (HR 1.80, 95% CI 
1.20 to 2.80, p=0.003) and low OS (HR 2.60, 95% CI 1.70 
to 4.10, p<0.001). Multivariable analyses confirmed these 
data after adjusting the impact of early use of steroids for 
other clinically relevant variables.
Our findings are consistent with the data of a recently 
published brief report which showed a negative impact of 
steroids use during the first 30 days of nivolumab treatment 
on the OS of patients with advanced NSCLC,29 and with 
other three independent studies in which use of steroids 
at the time of ICI initiation was associated with worse clin-
ical outcomes in the same clinical setting.19 20 30 There are 
several reasons why steroids can affect the outcomes of 
anti PD-1/PD-L1 therapy, including impairment of T-cell 
activation31 and inflammation,32 microbiome modifica-
tions,33 Th1 to Th2 phenotype skewing,34 35 and T regu-
latory cells recruitment.36 All these events, along with the 
capacity of corticosteroids to promote M2 macrophage 
polarisation,37 may restrain the efficacy of antitumour 
immunotherapy and lead to primary or adaptive resis-
tance to ICIs.38
Notably, assessing the overall impact of steroids use at 
any time during ICI treatment, we found no differences in 
patient outcomes, similar to what was previously reported 
by Leighl and colleagues.21 Different hypotheses can help 
explain these results, suggesting that steroids are unable 
to halt an effective antitumour immune response once 
they have been effectively induced by ICIs. First, immu-
notherapy is more efficacious in the presence of an intact 
immune system.39 For instance, Chen and colleagues40 
demonstrated that early on-treatment modifications in 
the efficiency of antigen presentation, T-cell activation 
and T-cell homing predict response to ICIs. Steroids 
could affect these important processes in the immune 
cascade, thus preventing the activation of an effective 
antitumour immune response if given precociously 
during ICI treatment. As well as being dose-dependent, 
the ability of corticosteroids in influencing T-cell survival 
is also cell cycle-dependent and time-dependent.41 There-
fore, after immunotherapy-mediated T-cell-boosted 
activation, effector cells may be protected from steroid-in-
duced apoptosis. We also found that the late-only use of 
steroids (after 28 days from ICI initiation) was associated 
with a better PFS and a trend towards a better OS with 
respect to no use of steroids. Of note, the main reason 
for the late use of steroids during the ICI treatment is 
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the management of irAEs, and several evidence linked 
the incidence of irAEs with better outcomes in patients 
with cancer treated with immunotherapy,42 43 explaining, 
at least in part, our observation.
Although steroid-induced increase in NLR and ANC 
has already been observed in patients with castration-re-
sistant prostate cancer,44 this is the first study reporting 
on the association between early use of steroids and 
modulation in peripheral blood immune cells at both 4 
and 6 weeks after ICI initiation. Since a high NLR/dNLR 
and a low REC at 4 and 6 weeks were consistently associ-
ated with reduced benefit from ICIs, our results suggest 
that early use of steroids could impair patient prognosis 
by modulating peripheral blood cells. In particular, the 
high number of blood neutrophils following steroids 
treatment may reflect the presence of myeloid-derived 
suppressive cells in tumour microenvironment. Corti-
costeroids are also able to upregulate the proportion of 
circulating CD4+/interleukin (IL)-17+ T cells,45 and IL-17 
can mediate an increase in tumour-associated neutrophils 
and resistance to PD-1 blockade.46 Steroids are known to 
induce apoptosis in eosinophils.47 We showed for the first 
time that, in patients with metastatic NSCLC treated with 
immunotherapy, an REC ≥1.5 at 4 and 6 weeks after ICI 
initiation has a positive impact on both PFS and OS, and 
is negatively associated with early use of steroids. These 
findings indicate that steroids can interfere with eosino-
phil-mediated immune homeostasis regulation, which in 
turn leads to a modulation of ICI efficacy.
The major critic to the postulation that the early use 
of steroids can impair ICI efficacy is that a precocious 
requirement of steroidal therapy as supportive care medi-
cation in patients with metastatic NSCLC could be due to 
a rapid clinical worsening/progression, being the early 
use of steroids the consequence, instead of the cause, 
of worse clinical outcomes. Our data about the modula-
tion of peripheral blood immune cells by the early use of 
steroids suggest an alternative hypothesis. Even if further 
studies (including appropriate preclinical investigation) 
are required to validate the role of neutrophils, lympho-
cytes and eosinophils modulation, our study suggests the 
biological basis behind the interaction between early use 
of steroids and ICI efficacy.
Although our study relies on a prospective registry, 
its main limitation consists in its retrospective nature. 
Prospective studies are therefore needed to definitely vali-
date the negative impact of early steroid use in patients 
treated with immunotherapy, as well as to assess its impli-
cation in patients treated with the combination of chemo-
therapy and ICIs.
In conclusion, we showed that the early use of steroids is 
associated with modulation in peripheral blood cells and 
significantly worse disease control, PFS and OS in patients 
with advanced NSCLC treated with ICIs. If confirmed by 
future studies, our findings should discourage the use of 
steroids during the first 4 weeks of ICI treatment in patients 
with advanced NSCLC. Since early initiation of steroids, 
or its chronic use, cannot be avoided in some patients, 
chemotherapy could be a preferred treatment option in 
these cases.
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